Protalix (PLX) Director Bar-Shalev Amos Receives 25,500 RSUs

What Happened

• Bar-Shalev Amos, a director of Protalix BioTherapeutics, was granted two awards on 2026-09-03 totaling 25,500 restricted stock units (17,000 RSUs + 8,500 RSUs). The reported acquisition price is $0.00, so no cash was paid. These are derivative awards (RSUs) that represent the right to receive common stock upon vesting.

Key Details

• Transaction date: 2026-09-03; Form 4 filed 2026-09-04 (timely filing).
• Award amounts and price: 17,000 RSUs @ $0.00 and 8,500 RSUs @ $0.00 (total 25,500 RSUs; reported value $0 at grant).
• Vesting: RSUs vest in 12 equal quarterly installments commencing on the grant date (12 quarters = 3 years).
• Shares owned after transaction: not specified in the provided filing summary.
• Other holdings (not part of this grant): the filing notes Amos holds various stock options (40,000 @ $3.55 exp. 1/20/2030; 50,000 @ $1.03 exp. 9/7/2032; 61,676 @ $1.66 exp. 9/29/2033; 15,000 @ $1.64 exp. 9/3/2035).

Context

• RSU grants are compensation/retention awards and are different from open-market purchases or sales; they do not represent an immediate cash outlay or sale of shares and only convert to actual shares as they vest. This type of award is usually routine director compensation and should not be read as a direct buy/sell signal.